english.prescrire.org > Spotlight > "Spotlight"
"Spotlight"

In the December issue of Prescrire International: Stable angina and antithrombotic drugs

FREE DOWNLOAD Addition of rivaroxaban (Xarelto°) to aspirin increases the risk of serious bleeding, but it has not been shown that the harm-benefit balance of this addition is favourable. Aspirin alone remains the first-choice antithrombotic drug in the majority of patients with coronary disease.
Full text available for free download.

Summary

  • In a randomised trial involving around 27 000 patients, most of whom had stable angina, with an average follow-up of 23 months, addition of rivaroxaban to low-dose aspirin led to a significant increase in serious bleeding.
     
  • Efficacy of rivaroxaban in this situation remains uncertain due to the methodological weaknesses of this trial.

Full text available for free download.

 ©Prescrire 1 December 2018

"Stable angina and antithrombotic drugs. Addition of rivaroxaban to aspirin: uncertain benefits, proven harms" Prescrire Int 2018; 27 (199): 298. (Pdf, free)

Share Share on Facebook Share on Twitter